Clinical Trials Task Force : run new investigator-initiated clinical trials
Cancer Core Europe investigators initiating clinical trials will benefit from expedited contracting and the ability to quickly open trials across all members’ centers.
These harmonized procedures aim to facilitate Cancer Core Europe’s interactions with pharmaceutical industry partners. Our expertise in clinical biostatistics and methodology will support innovative next-generation clinical trial design.
Profile patients according to molecular signatures and pathway alterations
Evaluate whether matching treatment to molecular abnormalities induces antitumor activity
Evaluate tumor heterogeneity, sensitivity, and resistance to treatment
Launch joint clinical trials
Follow-up patients using biopsies and liquid biopsies
Use innovative statistical designs in clinical trials with expert biostatistics support from within Cancer Core Europe